<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IOR-15006330</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-04-20</date_registration>
      <primary_sponsor>Department of Hematology, Xinqiao Hospital, Third Military Medical University</primary_sponsor>
      <public_title>Clinical application of Umbilical Cord-Derived Mesenchymal Stem Cells in the Prophylaxis of Chronic Graft-versus-Host Disease after HLA-haploidentical stem cell transplantation-A Prospective, Randomized, Parallel-group Study</public_title>
      <acronym />
      <scientific_title>Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stem Cells in the Prophylaxis of Chronic Graft-versus-Host Disease after HLA-haploidentical stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-08-01</date_enrolment>
      <type_enrolment />
      <target_size>MSCs group  :60;normal saline group  :60;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10892</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>Other</phase>
      <hc_freetext>Allogeneic hematopoietic stem cell transplantation patients with hematologic malignancies or non-hematologic malignancies</hc_freetext>
      <i_freetext>MSCs group  :patients received 4 cycles umbilical cord-derived MSCs (1*10^7 per month) from 4 to 7 months after transplantation;normal saline group  :Patients received 4 cycles normal saline(100ml per month) from 4 to 7 months after transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Lei Gao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Street, Chongqing Municipality, China</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13228689635</telephone>
        <email>gaolei7765@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xi Zhang</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Street, Chongqing Municipality, China</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13808310064</telephone>
        <email>gaolei7765@163.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1.Allogeneic HSCT patients did not occured cGVHD;
2.age between 18 to 60;
3.KPS score &gt; 60;
4.No serious organ dysfunction;
5.Expected survival &gt;3 months.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1.Have serious organ dysfunction;
2.Combined with other cancer need treatment;
3.Presence of clinical signs of brain dysfunction or severe mental illness can not understand or comply with the study protocol;
4.Can not scheduled follow-up;
5.Can not guarantee the completion of the treatment plan and the necessary follow-up observation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Chronic graft versus host disease;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>relapse;Overall survival;Disease free survival;Lymphocyte subset;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Strategic Priority Research Program of Chinese Academy of Sciences, Grant No. XDA01000000</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-08-22</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>